Zimmer Biomet Holdings (ZBH) 10-K Summary — Year Ended Dec 31, 2023
The filing covers the company's annual financial results and business overview. The company reported revenue growth and improved operating cash flow.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
The filing covers the company's annual financial results and business overview. The company reported revenue growth and improved operating cash flow.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$7.4B
Revenue reported for the fiscal year.
Operating income
$1.3B
Income from operations reported for the year.
Net income
$1B
Net income reported for the year.
Operating cash flow
$1.6B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $6.8B | n/a |
| Dec 31, 2022 | $6.9B | +1.6% |
| Dec 31, 2023 | $7.4B | +6.5% |
Business overview
The supplied filing context includes a reference to the business overview section but does not contain the substantive description of the company's operations.
Financial performance
Revenue increased compared to the prior year, and operating income and net income were reported. Cash flow from operations also improved.
Material risks
The filing cautions that forward-looking statements involve risks and uncertainties and that actual results may differ. No specific risk factors are detailed in the supplied context.
Liquidity and capital
The company held cash and had access to credit facilities, with operating cash flow supporting its liquidity. It believes its capital resources are sufficient for the near term.
What to watch
The upcoming maturity of the company's short-term revolving credit facility is a key item to monitor in the next filing.